Latest Safety News

VRX Silica Limited has announced a strategic leadership transition with Tony Swiericzuk appointed as CEO, succeeding Bruce Maluish who will step down in 2026 but remain on the board. This move positions VRX to advance its Arrowsmith North silica sand project towards production.

TrivarX has received $3.5 million in second-tranche placement funding, enabling advancement of its innovative Stabl-Im technology for early, non-invasive brain tumour detection. The funding supports manufacturing scale-up and regulatory preparations ahead of a planned Phase 1 clinical trial in 2026.

Regis Healthcare announces the resignation of CEO Dr Linda Mellors after six years, with a transition period underway as the board searches for her successor.

Cyclopharm Limited has secured regulatory approval for its Technegas lung imaging technology in Colombia, marking its presence in 67 countries worldwide. This milestone aligns strategically with the upcoming global nuclear medicine congress in Cartagena.

BioMarin Pharmaceutical’s acquisition of Amicus Therapeutics for US$4.8 billion includes Dimerix’s US licensing agreement, promising significant milestone payments and royalties. This deal strengthens Dimerix’s position as it advances its Phase 3 kidney disease therapy.

INOVIQ Limited has reported compelling preclinical results for its CAR-NK-exosome therapy targeting triple-negative breast cancer, showing significant tumor reduction and perfect survival in treated mice.

Immutep Limited reports encouraging Phase I results for IMP761, a novel LAG-3 agonist antibody targeting autoimmune diseases, demonstrating dose-dependent immunosuppression and a strong safety profile. Further trial updates are expected in early 2026.

RemSense Technologies has secured a follow-up contract with ExxonMobil to deliver advanced digital twin solutions at the Bass Strait facility, reinforcing its role in the energy sector’s digital transformation.

Rox Resources has strategically purchased gold put options covering half of its forecast production at the Youanmi Gold Project for FY2028, locking in price protection while retaining upside exposure.

Biotron Limited has closed its non-renounceable rights issue, raising $645,861 to advance its Hepatitis B virus drug development, with a shortfall commitment from Peak Asset Management still pending.

Downer EDI Limited has been named preferred contractor for four major New Zealand state highway maintenance contracts, securing an estimated NZD 870 million in revenue over initial contract periods starting May 2026.

Scout Security outlines a bold transformation with the acquisition of Roo Inc., expansion into insuretech, and a pivot to AI-driven smart security solutions, positioning itself for accelerated growth and profitability.